number of weight loss drug prescriptions q3 2024 semaglutide tirzepatide as Compared with for the Treatment Obesity Alternative dosing regimens of GLP-1
Description
Daily drops become part of a morning/evening routine
Among tirzepatide users, females accounted for 74.9% of high responders and 59.2% of minimal responders
All of the above is protected by U.S
GLP-1 agonist drug sales increased 58.2% between December 2022 and December 2023, with Ozempic and Mounjaro driving most of that growth volume
You do not need to visit a clinic
